Southampton based research firm, Synairgen, has rocketed in morning trading after announcing results for a treatment which could protect asthmatics from respiratory virus infections.
The drug, called SNG001, stops infections like the common cold spreading to patients' lungs, which is often the cause of hospital admissions for asthma sufferers.
The study investigated SNG001 in a population of 134 adult asthma patients, representing 'mild-moderate' through to 'severe' asthmatics, who caught a cold.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Patients with 'difficult to treat' asthma, being approximately half of the patients in the trial, benefitted significantly from SNG001 treatment. This category of patient is estimated to represent between 10% and 20% of all adult asthma sufferers.
Professor Stephen Holgate, the founder of Synairgen, said: "This is the first clinical study which appears to demonstrate that, by boosting the antiviral defences of the lungs of asthmatics...we can...prevent worsening of asthma symptoms in a high risk group of patients."
He'll certainly have been breathing easily after looking at his firm's share price this morning, the stock had gained 27.6% by 10:59.
BS
-
Trump’s tariffs: what is he thinking and how should UK respond?Every right-thinking person knows that free trade is a surer route to the wealth of nations than protectionism, says Stuart Watkins. What is Trump thinking?
-
Barclays begins paying up to £100 compensation to customers after banking outageBarclays will pay up to £7.5 million in compensation to customers after its banking services were disrupted by an IT outage
